Responses With Asciminib Continue to Deepen Over Time in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) After ≥2 Prior Tyrosine Kinase Inhibitors (TKIs) in the Phase III ASCEMBL Study

被引：0
|
作者：
Mauro, Michael [1 ]
Hochhaus, Andreas [2 ]
Hughes, Timothy [3 ,4 ]
Rea, Delphine [5 ]
Boquimpani, Carla [6 ]
Minami, Yosuke [7 ]
Apperley, Jane [8 ]
Garcia-Gutierrez, Valentin [9 ]
Kapoor, Shruti [10 ]
Espurz, Noemi [11 ]
Dhamal, Vishal [12 ]
Cortes, Jorge [13 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, New York, NY USA
[2] Univ Klinikum Jena, Jena, Germany
[3] South Australian Hlth & Med Res Inst, Adelaide, SA, Australia
[4] Univ Adelaide, Adelaide, SA, Australia
[5] Hop St Louis, Paris, France
[6] State Inst Hematol Arthur Siquiera Cavalcanti, HEMORIO, Rio De Janeiro, Brazil
[7] Natl Canc Ctr Hosp East, Kashiwa, Chiba, Japan
[8] Ctr Haematol Imperial Coll London, London, England
[9] Hosp Univ Ramon & Cajal IRYCIS, Serv Hematol, Madrid, Spain
[10] Novartis Pharmaceut, E Hanover, NJ USA
[11] Novartis Pharma AG, Basel, Switzerland
[12] Novartis Healthcare Private Ltd, Hyderabad, India
[13] Georgia Canc Ctr, Augusta, GA USA
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2023年 / 23卷
关键词：
CML; asciminib; TKI; ASCEMBL; phase III;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CML-398
引用
收藏
页码：S340 / S340
页数：1
相关论文
共 50 条
  • [31] Determinants of frontline tyrosine kinase inhibitor choice for patients with chronic-phase chronic myeloid leukemia: A study from the Registro Italiano LMC and Campus CML
    Tiribelli, Mario
    Latagliata, Roberto
    Breccia, Massimo
    Capodanno, Isabella
    Miggiano, Maria Cristina
    Cavazzini, Francesco
    Bucelli, Cristina
    Attolico, Immacolata
    Crescenzi, Sabrina Leonetti
    Russo, Sabina
    Annunziata, Mario
    Sora, Federica
    Bonifacio, Massimiliano
    Mulas, Olga
    Loglisci, Giuseppina
    Maggi, Alessandro
    Binotto, Gianni
    Crisa, Elena
    Scortechini, Anna Rita
    Leporace, Anna Paola
    Sancetta, Rosaria
    Murgano, Pamela
    Abruzzese, Elisabetta
    Stagno, Fabio
    Rapezzi, Davide
    Luzi, Debora
    Vincelli, Iolanda
    Bocchia, Monica
    Fava, Carmen
    Malato, Alessandra
    Crugnola, Monica
    Pizzuti, Michele
    Lunghi, Francesca
    Galimberti, Sara
    Dalmazzo, Matteo
    Fanin, Renato
    Scalzulli, Emilia
    Foa, Robin
    Iurlo, Alessandra
    Saglio, Giuseppe
    Specchia, Giorgina
    CANCER, 2023, 129 (17) : 2637 - 2644
  • [32] DASFREE: Treatment-Free Remission (TFR) After Discontinuation of Dasatinib in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) and Deep Molecular Response (DMR)
    Shah, Neil P.
    Garcia-Gutierrez, Valentin
    Jimenez-Velasco, Antonio
    Larson, Sarah
    Saussele, Susanne
    Rea, Delphine
    Mahon, Francois-Xavier
    Levy, Moshe Yair
    Teresa Gomez-Casares, Maria
    Luciano, Luigia
    Nicolini, Franck-Emmanuel
    Mauro, Michael J.
    Sy, Oumar
    Martin-Regueira, Patricia
    Lipton, Jeffrey H.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 : S299 - S299
  • [33] Clinical Development of Asciminib (ABL001): A Randomized Phase 3 Study of Asciminib vs Bosutinib in Patients with Chronic Myeloid Leukemia (CML)
    Mauro, Michael J.
    Lang, Fabian
    Kim, Dong-Wook
    Cortes, Jorge E.
    Hughes, Timothy P.
    Hochhaus, Andreas
    Minami, Hironobu
    Boquimpani, Carla
    Minami, Yosuke
    Breccia, Massimo
    Goh, Yeow-Tee
    Ottmann, Oliver
    Sondhi, Manu
    Hois, Stephan
    Bedoucha, Veronique
    Perraud, Kevin
    Rea, Delphine
    DeAngelo, Daniel J.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2018, 18 : S223 - S223
  • [34] Therapy for patients with chronic phase-chronic myeloid leukemia previously treated with ≥2 tyrosine kinase inhibitors: a systematic literature review
    Atallah, Ehab
    Saini, Lovneet
    Maegawa, Rodrigo
    Rajput, Tanvi
    Corbin, Regina
    Viana, Ricardo
    THERAPEUTIC ADVANCES IN HEMATOLOGY, 2023, 14
  • [35] JAK2-Unmutated Erythrocytosis in Chronic Phase Myeloid Leukemia (CP-CML) During Tyrosine Kinase Inhibitor (TKI) Treatment
    Kulemina, Olga
    Yakovleva, Julia
    Lazorko, Natalia
    Chitanava, Tamara
    Siordia, Nadia
    Shnalieva, Nadezhda
    Tochenaya, Elena
    Mateikovich, Polina
    Lomaia, Elza
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S343 - S344
  • [36] ASC2ESCALATE: A US, Phase II Open-Label, Single-Arm, Dose-Escalation Study of Asciminib Monotherapy in Second-Line (2L) and First-Line (1L) Treatment of Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP)
    Atallah, Ehab
    Mauro, Michael
    Sasaki, Koji
    Levy, Moshe
    Koller, Paul
    Yang, Daisy
    Laine, Dramane
    Sabo, John
    Gu, Ennan
    Cortes, Jorge
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S348 - S349
  • [37] Treatment-Free Remission (TFR) Following Frontline Nilotinib in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP): 192-Weeks Data from the ENESTfreedom Study
    Radich, Jerald P.
    Ross, David M.
    Masszi, Tamas
    Gomez Casares, Maria Teresa
    Hellmann, Andrzej
    Stentoft, Jesper
    Conneally, Eibhlin
    Garcia Gutierrez, Valentin
    Gattermann, Norbert
    Le Coutre, Philipp D.
    Martino, Bruno
    Saussele, Susanne
    Giles, Francis J.
    Saglio, Giuseppe
    Sondhi, Manu
    Mishra, Kaushal
    Aimone, Paola
    Hochhaus, Andreas
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 : S288 - S288
  • [38] Asciminib After Two or More Prior Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia: Real-World Evaluation of Treatment Patterns and Clinical Outcomes in US Clinical Practice
    Atallah, Ehab L.
    Wei, David
    Latremouille-Viau, Dominick
    Rossi, Carmine
    Damon, Andrea
    Ferreira, Germano
    Guerin, Annie
    Jadhav, Kejal
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S367 - S368
  • [39] ENESTop 192-Weeks Results: Treatment-Free Remission (TFR) in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) After Stopping Second-Line Nilotinib
    Mahon, Francois-Xavier
    Boquimpani, Carla
    Takahashi, Naoto
    Benyamini, Noam
    Clementino, Nelma Cristina D.
    Shuvaev, Vasily
    Lipton, Jeffrey H.
    Turkina, Anna G.
    De Paz Arias, Raquel
    Moiraghi, Beatriz
    Nicolini, Franck E.
    Dengler, Jolanta
    Sacha, Tomasz
    Kim, Dong-Wook
    Fellague-Chebra, Rafik
    Tiwari, Ranjan
    Bouard, Catherine
    Hughes, Timothy P.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 : S288 - S289
  • [40] The EMA Assessment of Asciminib for the Treatment of Adult Patients With Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase Who Were Previously Treated With at Least Two Tyrosine Kinase Inhibitors
    Tesileanu, C. Mircea S.
    Michaleas, Sotirios
    Ruiz, Rocio Gonzalo
    Mariz, Segundo
    Fabriek, Babs O.
    van Hennik, Paula B.
    Dedorath, Jutta
    Dekic, Bruna
    Unkrig, Christoph
    Brandt, Andreas
    Koenig, Janet
    Enzmann, Harald
    Delgado, Julio
    Pignatti, Francesco
    ONCOLOGIST, 2023, 28 (07) : 628 - 632
12345